FDA says Advance-Esthetic markets three Zemits body-contouring devices without the required FDA clearance or approval.
What happened
FDA inspected the firm's Fort Lauderdale, Florida facility from October 27, 2025 through November 6, 2025. FDA also reviewed the firm's device listings and its website, and found the Zemits CrystalFrax Pro, Abigon Pro and Bionexis Lite Pro marketed for body contouring, cellulite, stretch marks and collagen stimulation. The firm had listed them as therapeutic massagers, a type exempt from premarket review, but FDA says these devices use radiofrequency and light technology and different intended uses, so the exemption does not apply.
What FDA found
The devices are adulterated because the firm has no approved premarket approval (PMA) application, the FDA review required for high-risk devices.
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The firm also has no approved investigational device exemption (IDE), the approval needed to study an unapproved device in humans.
Section 520(g) of the Act, 21 U.S.C. § 360j(g)The devices are misbranded because the firm did not tell FDA it intended to put them into commercial distribution, as required by the 510(k) premarket notification process.
Section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)The devices do not fit the therapeutic massager exemption because they work by radiofrequency energy and light rather than air-pressure massage.
21 CFR 890.9(b)The devices do not fit the exemption because they are marketed for uses such as reducing cellulite and boosting collagen, which are not the intended uses of legally marketed therapeutic massagers.
21 CFR 890.9(a); 21 CFR 807.81(a)(3)(i)
What FDA wants
Within 15 business days of receiving the letter, the firm must write to FDA describing the steps taken to fix the violations, how it will prevent them from recurring, and documentation of those corrections, or explain why more time is needed. FDA says a follow-up inspection will be required to check whether the corrections are adequate.
Who should pay attention
- medical spas, salons and clinics buying radiofrequency or light-based body-contouring devices
- distributors and resellers of Zemits or similar aesthetic devices
- regulatory teams deciding whether a device qualifies for a 510(k) exemption
This is a summary. Read the original letter on fda.gov.